Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Sweeping Success with Artificial Gene Switches - Heidelberg Students Score at International Competition

No. 52 | 09/11/2009 | by (Koh)

At the high-profile international competition in synthetic biology (iGEM) held by the Massachusetts Institute of Technology in Boston, the Heidelberg team of undergraduates has reached a sensational second place in the overall evaluation. Moreover, the team headed by Professor Roland Eils of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and Heidelberg University has been awarded prizes for the best new standard and the best internet presentation (wiki). Thus, the Heidelberg team outperformed all other teams from top universities in the U.S. and Asia

The Team from Heidelberg
© dkfz.de

iGEM – this acronym stands for the world’s most important student competition in synthetic biology: the “International Competition of Genetically Engineered Machines”. More than 110 teams from the world’s leading universities with over 1,100 students came to Boston at the past weekend to participate in MIT’s high-profile competition in this young and future-oriented science discipline.

Heidelberg reached a sensational second place in the overall performance and was 1st runner up to the team from Cambridge, U.K., which won the Grand Prize. Moreover, the students from Heidelberg were awarded the prizes for Best New Standard and Best Wiki. Last year, the Heidelberg team participated for the first time and won three special prizes straight away so that it was considered a top candidate in this year’s competition from the beginning. The team met the expectations supremely well.

Like in the construction of an aircraft, where many prefabricated parts are assembled, synthetic biology uses simple genetic building blocks and combines these to engineer new complex systems with specific functions. The Heidelberg team had set itself a very ambitious goal this year. Instead of working with bacteria, which have a comparatively simple construction, they attempted to design artificial gene switches for mammalian cells. “Working with mammalian cells is particularly important for us here in Heidelberg, because we aim to apply the methods of synthetic biology in cancer research, too,” says project leader Roland Eils. With their award-winning project, the Heidelberg scientists have laid an important cornerstone for applying the concepts of synthetic biology to human cells.

Gene switches, scientifically called promoters, play a central role in the regulation of all cell activities and are thus of prime interest in synthetic biology. Gene switches are areas of genetic material which contain a whole number of docking sites for various regulatory proteins. When these proteins bind to the appropriate docking sites, the structure of the genetic material changes and the respective gene can be read. Promoters regulate when and in which cell type the respective gene is read. By selectively switching specific genes on or off, scientists are able to interfere with specific cellular signaling pathways, e.g. to correct misguided processes in cancer cells.

The thirteen participants of the Heidelberg team have been working on their “Spybricks” project since February in laboratories of the Bioquant Institute. The first aim of the students was to generate new promoter sequences on a random basis and to try out how well these newly created switches function to activate a gene. To this end, the team developed a novel chemical synthesis method in which several DNA sequences with slight differences in the sequence of building blocks are produced from each preparation. Subsequently, the functioning of the different versions in the cell was tested. In another part of the project, the Heidelberg team used computer-aided methods to design promoters to which very specific regulatory proteins can bind. The aim is to create gene switches which react only to exactly defined stimuli. Here, too, the Heidelberg participants were already able to verify the functioning of the switches in cell experiments.

The sequences of all newly synthesized gene switches have been compiled in a library which is now available for use as “biological building blocks” by all scientists in the area of synthetic biology.

The “Spybrick” project and the promoter library are found on the Internet at:
http://2009.igem.org/Team:Heidelberg

A picture for this press release is available on the Internet at:
http://www.dkfz.de/de/presse/pressemitteilungen/2009/images/iGEM_2009.jpg

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS